Timothy A Chan Selected Research

Bevacizumab (Avastin)

10/2018	Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.
11/2017	Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.
10/2014	Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.
2/2013	Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Timothy A Chan Research Topics

Disease

148	Neoplasms (Cancer) 12/2023 - 03/2002
25	Glioma (Gliomas) 01/2023 - 01/2007
16	Glioblastoma (Glioblastoma Multiforme) 10/2023 - 07/2005
14	Melanoma (Melanoma, Malignant) 01/2019 - 12/2014
11	Carcinoma (Carcinomatosis) 10/2023 - 08/2012
11	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 03/2002
11	Brain Neoplasms (Brain Tumor) 05/2019 - 02/2012
8	Neoplasm Metastasis (Metastasis) 01/2023 - 02/2012
8	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 11/2016
8	Carcinogenesis 01/2020 - 03/2002
6	Squamous Cell Carcinoma of Head and Neck 10/2023 - 11/2011
5	Breast Neoplasms (Breast Cancer) 01/2022 - 03/2011
5	Lung Neoplasms (Lung Cancer) 06/2019 - 04/2015
5	Astrocytoma (Pilocytic Astrocytoma) 01/2019 - 05/2012
4	Disease Progression 10/2023 - 02/2012
4	Urinary Bladder Neoplasms (Bladder Cancer) 10/2023 - 10/2012
4	Thyroid Neoplasms (Thyroid Cancer) 01/2022 - 09/2013
3	Salivary Gland Neoplasms (Salivary Gland Cancer) 12/2023 - 07/2013
3	Adenocarcinoma 01/2020 - 06/2014
3	Head and Neck Neoplasms (Head and Neck Cancer) 06/2019 - 11/2011
2	Adenoid Cystic Carcinoma (Cylindroma) 12/2023 - 01/2020
2	Hypoxia (Hypoxemia) 11/2023 - 01/2021
2	Inflammation (Inflammations) 10/2023 - 10/2022
2	COVID-19 01/2022 - 01/2021
2	Microsatellite Instability 10/2021 - 01/2019
2	Kidney Neoplasms (Kidney Cancer) 06/2021 - 01/2021
2	Infections 01/2021 - 01/2020
2	Communicable Diseases (Infectious Diseases) 11/2019 - 11/2017
2	Cysts 01/2019 - 02/2016
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2016 - 02/2012
2	Parkinson Disease (Parkinson's Disease) 04/2010 - 01/2010
2	Colonic Neoplasms (Colon Cancer) 06/2006 - 03/2002
1	Tuberous Sclerosis (Bourneville's Disease) 11/2023

Drug/Important Bio-Agent (IBA)

39	Immune Checkpoint InhibitorsIBA 11/2023 - 12/2014
27	Biomarkers (Surrogate Marker)IBA 10/2023 - 06/2009
16	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 09/2007
12	RNA (Ribonucleic Acid)IBA 12/2023 - 06/2015
9	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2010
9	AntigensIBA 11/2022 - 02/2016
8	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2020 - 02/2012
8	Temozolomide (Temodar)FDA LinkGeneric 10/2018 - 02/2012
7	ChromatinIBA 01/2023 - 07/2013
6	Peptides (Polypeptides)IBA 11/2023 - 02/2015
6	pembrolizumabIBA 10/2023 - 04/2015
6	InterferonsIBA 01/2022 - 08/2015
6	HLA Antigens (Human Leukocyte Antigens)IBA 12/2021 - 01/2018
5	T-Cell Antigen Receptors (T-Cell Receptor)IBA 12/2023 - 02/2015
5	IpilimumabIBA 12/2023 - 12/2014
4	EnzymesIBA 01/2019 - 05/2013
4	Bevacizumab (Avastin)FDA Link 10/2018 - 02/2013
4	Messenger RNA (mRNA)IBA 01/2017 - 01/2015
4	Protein Tyrosine PhosphatasesIBA 06/2014 - 10/2009
3	LigandsIBA 01/2024 - 01/2021
3	Histones (Histone)IBA 01/2023 - 02/2012
3	Transcription Factors (Transcription Factor)IBA 11/2022 - 01/2020
3	Neoplasm Antigens (Tumor Antigens)IBA 01/2020 - 01/2018
3	MethyltransferasesIBA 10/2018 - 02/2012
3	Class 2 Receptor-Like Protein Tyrosine PhosphatasesIBA 01/2015 - 06/2009
3	Phosphoric Monoester Hydrolases (Phosphatases)IBA 05/2014 - 06/2009
3	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 06/2006 - 03/2002
2	NivolumabIBA 12/2023 - 11/2017
2	CytokinesIBA 10/2023 - 04/2022
2	Cadherins (E-Cadherin)IBA 01/2023 - 03/2013
2	Interleukin-15 (Interleukin 15)IBA 08/2022 - 01/2022
2	Granzymes (Granzyme)IBA 01/2022 - 01/2019
2	AntibodiesIBA 01/2022 - 12/2014
2	Double-Stranded RNA (RNA, Double Stranded)IBA 01/2022 - 08/2015
2	EpitopesIBA 01/2022 - 11/2017
2	Small Cytoplasmic RNAIBA 10/2021 - 01/2021
2	5'-N-methylcarboxamideadenosineIBA 01/2020 - 10/2017
2	VaccinesIBA 01/2020 - 03/2015
2	Formaldehyde (Formol)FDA Link 12/2018 - 08/2012
2	Tyrosine Kinase InhibitorsIBA 12/2018 - 06/2014
2	ParaffinIBA 12/2018 - 08/2012
2	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2017 - 01/2010
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 06/2014 - 11/2011
2	ErbB Receptors (EGF Receptor)IBA 05/2014 - 11/2011
2	delta Opioid Receptors (delta Opioid Receptor)IBA 05/2014 - 02/2012
2	Cetuximab (Erbitux)FDA Link 05/2014 - 11/2011
2	Decitabine FDA Link 04/2014 - 10/2013
2	Azacitidine (5 Azacytidine)FDA Link 04/2014 - 10/2013
2	alpha-hydroxyglutarateIBA 10/2013 - 02/2012
2	CateninsIBA 05/2013 - 03/2013
2	Calcibiotic Root Canal SealerIBA 08/2012 - 06/2009
2	Tyrosine (L-Tyrosine)FDA Link 02/2012 - 06/2009
2	Tumor Biomarkers (Tumor Markers)IBA 01/2012 - 09/2007
2	Cyclin EIBA 04/2010 - 01/2010
2	beta CateninIBA 06/2006 - 06/2002
1	Endothelial Protein C ReceptorIBA 11/2023
1	Mechanistic Target of Rapamycin Complex 1IBA 11/2023
1	Radioisotopes (Radionuclides)IBA 11/2023
1	RadiopharmaceuticalsIBA 11/2023

Therapy/Procedure

53	Therapeutics 11/2023 - 01/2013
47	Immunotherapy 11/2023 - 02/2015
22	Radiotherapy 01/2021 - 07/2005
10	Drug Therapy (Chemotherapy) 10/2023 - 01/2012
2	Aftercare (After-Treatment) 01/2021 - 07/2009
2	Chemoradiotherapy 01/2021 - 01/2019
2	Nephrectomy 01/2020 - 01/2019
2	Brachytherapy 01/2007 - 07/2005